NCT01087593

Brief Summary

In order to evaluate the potential effects of estrogen treatment in postmenopausal women with fibromyalgia, the investigators used quantitative sensory tests before and after eight weeks of estrogen treatment as compared with placebo treatment.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
29

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Aug 2001

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2001

Completed
6.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2007

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2007

Completed
2.5 years until next milestone

First Submitted

Initial submission to the registry

March 15, 2010

Completed
1 day until next milestone

First Posted

Study publicly available on registry

March 16, 2010

Completed
Last Updated

March 16, 2010

Status Verified

September 1, 2001

Enrollment Period

6.2 years

First QC Date

March 15, 2010

Last Update Submit

March 15, 2010

Conditions

Keywords

estrogensubstitutionpainhormonal levelsquantitative sensory testing

Outcome Measures

Primary Outcomes (1)

  • Pain thresholds and pain tolerance

    Before and after eight weeks treatment

Study Arms (2)

Treatment with transdermal 17β-estradiol

EXPERIMENTAL
Drug: 17β-estradiol

Control

PLACEBO COMPARATOR
Drug: 17β-estradiol

Interventions

Transdermal administration(50 ug daily)for a period of ten weeks with additional treatment of medroxyprogesterone (10mg daily) for the last two weeks

Also known as: Evorel, provera
ControlTreatment with transdermal 17β-estradiol

Eligibility Criteria

Age40 Years - 60 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Between 49-60 years
  • Body mass index (BMI) of \< 30
  • Met the ACR-90 criteria for the diagnosis of fibromyalgia
  • Postmenopausal state since at least six months
  • Not been using any hormonal treatments for the past three months
  • Had normal mammography screenings

You may not qualify if:

  • Using psychotropic drugs or having a history of thromboembolism
  • Diabetes mellitus, polyneuropathy, chronic liver disease,
  • Alcohol or substance abuse, hemoglobinopathy,
  • Endometrial adenomatous hyperplasia, or malignancy.
  • Presence of untreated hypertension (\>160/95).
  • Undiagnosed vaginal bleedings

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University hospital in Linköping

Linköping, 581 85, Sweden

Location

Related Publications (1)

  • Stening KD, Eriksson O, Henriksson KG, Brynhildsen J, Lindh-Astrand L, Berg G, Hammar M, Amandusson A, Blomqvist A. Hormonal replacement therapy does not affect self-estimated pain or experimental pain responses in post-menopausal women suffering from fibromyalgia: a double-blind, randomized, placebo-controlled trial. Rheumatology (Oxford). 2011 Mar;50(3):544-51. doi: 10.1093/rheumatology/keq348. Epub 2010 Nov 14.

MeSH Terms

Conditions

FibromyalgiaPain

Interventions

EstradiolMedroxyprogesterone Acetate

Condition Hierarchy (Ancestors)

Muscular DiseasesMusculoskeletal DiseasesRheumatic DiseasesNeuromuscular DiseasesNervous System DiseasesNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

EstrenesEstranesSteroidsFused-Ring CompoundsPolycyclic CompoundsEstradiol CongenersGonadal Steroid HormonesGonadal HormonesHormonesHormones, Hormone Substitutes, and Hormone AntagonistsMedroxyprogesteroneHydroxyprogesteronesProgesteronePregnenedionesPregnenesPregnanes

Study Officials

  • Mats Hammar, MD, prof

    University Hospital, Linkoeping

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

March 15, 2010

First Posted

March 16, 2010

Study Start

August 1, 2001

Primary Completion

October 1, 2007

Study Completion

October 1, 2007

Last Updated

March 16, 2010

Record last verified: 2001-09

Locations